Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
14 Oct 2023
14 Oct 2023
Historique:
received:
18
04
2023
accepted:
26
09
2023
medline:
15
10
2023
pubmed:
15
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response prediction. The role of soluble CD40 (sCD40) is unknown in PDAC. In this study, we performed a quantitative multiplex analysis of 17 immune checkpoint proteins in serum samples from patients with various stages of PDAC in a discovery study (n = 107) and analyzed sCD40 by ELISA in a validation study (n = 317). Youden's J statistic was used for diagnostic cut-off optimization. A Cox proportional hazards regression model was applied in an empiric approach for prognostic threshold optimization. Kaplan-Meier estimator and multivariable Cox regression analyses were used for survival analysis. sCD40 was significantly increased in the serum of patients with PDAC compared to healthy cohorts and patients with IPMN. In the validation cohort, the area under the receiver operating characteristic (ROC) c-statistic was 0.8, and combining sCD40 with CA19-9 yielded a c-statistic of 0.95. sCD40 levels were independent of the tumor stage. However, patients who received neoadjuvant chemotherapy had significantly lower sCD40 levels than those who underwent upfront surgery. Patients with a sCD40 level above the empirical threshold of 0.83 ng/ml had a significantly reduced overall survival with a hazard ratio of 1.4. This observation was pronounced in patients after neoadjuvant chemotherapy. Collectively, soluble CD40 may be considered as both a diagnostic and prognostic non-invasive biomarker in PDAC.
Identifiants
pubmed: 37838778
doi: 10.1038/s41698-023-00459-9
pii: 10.1038/s41698-023-00459-9
pmc: PMC10576756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SE2980/5-1
Informations de copyright
© 2023. Nature Publishing Group UK.
Références
American Cancer Society. Cancer Facts & Figures 2022, Vol. 80 (American Cancer Society, 2022).
Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014).
pubmed: 24840647
Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).
pubmed: 32732879
pmcid: 7393098
Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).
pubmed: 33811120
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
pubmed: 28596308
pmcid: 5576142
O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431–1438 (2019).
pubmed: 31318392
pmcid: 6647002
Hu, Z. I. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin. Cancer Res. 24, 1326–1336 (2018).
pubmed: 29367431
pmcid: 5856632
Bockorny, B., Grossman, J. E. & Hidalgo, M. Facts and hopes in immunotherapy of pancreatic cancer. Clin. Cancer Res. OF1–OF12 https://doi.org/10.1158/1078-0432.CCR-21-3452 (2022).
Di Caro, G. et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 65, 1710–1720 (2016).
pubmed: 26156960
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D. & Hingorani, S. R. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 5, 978–991 (2017).
pubmed: 29066497
pmcid: 5802342
Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).
pubmed: 29132146
pmcid: 6145146
Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289–307.e9 (2020).
pubmed: 32183949
pmcid: 7181337
Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. 217, e20190673 (2020).
pubmed: 32453421
pmcid: 7398166
Byrne, K. T. & Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15, 2719–2732 (2016).
pubmed: 27292635
pmcid: 4917417
Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612–1616 (2011).
pubmed: 21436454
pmcid: 3406187
Long, K. B. et al. IFNγ and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 6, 400–413 (2016).
pubmed: 26896096
pmcid: 4843521
Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035–1043 (2013).
pubmed: 23460534
pmcid: 3590838
Beatty, G. L. et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 19, 6286–6295 (2013).
pubmed: 23983255
O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021).
pubmed: 33387490
Padrón, L. J. et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167–1177 (2022).
pubmed: 35662283
pmcid: 9205784
Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008–2020 (2020).
pubmed: 32593337
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA: Cancer J. Clin. 72, 7–33 (2022).
pubmed: 35020204
Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J. Gastrointest. Oncol. 3, 105–119 (2012).
pubmed: 22811878
pmcid: 3397644
US Preventive Services Task Force. Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement. J. Am. Med. Assoc. 322, 438–444 (2019).
Kim, J.-E. et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 19, 182–186 (2004).
pubmed: 14731128
Al-Shaheri, F. N. et al. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Cancer Treat. Rev. 96, 102193 (2021).
pubmed: 33865174
Brand, R. E. et al. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 17, 805–816 (2011).
pubmed: 21325298
pmcid: 3075824
Honda, K. et al. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci. Rep. 5, 15921 (2015).
pubmed: 26549697
pmcid: 4637825
Poruk, K. E. et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. Med. 13, 340–351 (2013).
pubmed: 23331006
pmcid: 4419808
Belfiori, G. et al. Long-term survivors after upfront resection for pancreatic ductal adenocarcinoma: an actual 5-year analysis of disease-specific and post-recurrence survival. Ann. Surg. Oncol. 28, 8249–8260 (2021).
pubmed: 34258720
Mi, H. et al. Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers. Cancer Res. 82, 4359–4372 (2022).
pubmed: 36112643
pmcid: 9716253
Liudahl, S. M. et al. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. Cancer Discov. 11, 2014–2031 (2021).
pubmed: 33727309
pmcid: 8338775
Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178–1191 (2022).
pubmed: 35902743
pmcid: 10290535
Machiraju, D. et al. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. OncoImmunology 10, 1926762 (2021).
pubmed: 34104542
pmcid: 8158029
Gu, D., Ao, X., Yang, Y., Chen, Z. & Xu, X. Soluble immune checkpoints in cancer: production, function and biological significance. J. ImmunoTher. Cancer 6, 132 (2018).
pubmed: 30482248
pmcid: 6260693
Ugurel, S. et al. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. Annal. Oncol. 31, 144–152 (2020).
Xiong, W., Gao, Y., Wei, W. & Zhang, J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer 7, 837–846 (2021).
pubmed: 33903073
Kruger, S. et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. OncoImmunology 6, e1310358 (2017).
pubmed: 28638732
pmcid: 5467983
Bian, B. et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. OncoImmunology 8, e1561120 (2019).
pubmed: 30906655
pmcid: 6422385
Chung, H. W. & Lim, J.-B. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. J. Transl. Med. 12, 102 (2014).
pubmed: 24745825
pmcid: 4021610
Wang, Q. et al. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J. ImmunoTher. Cancer 7, 334 (2019).
pubmed: 31783776
pmcid: 6884764
Seifert, A. M. et al. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene 39, 3102–3113 (2020).
pubmed: 32055023
pmcid: 7142017
Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245–1252 (2005).
pubmed: 16286920
Meltzer, S. et al. The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. Br. J. Cancer 125, 240–246 (2021).
pubmed: 33837301
pmcid: 8292313
Hock, B. D. et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 106, 2148–2157 (2006).
pubmed: 16598754
Heiduk, M. et al. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. JCI Insight 7, e152761 (2022).
pubmed: 36509285
pmcid: 9746809
Dias Costa, A. et al. Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer. Clin. Cancer Res. 28, 5167–5179 (2022).
pubmed: 36129461
Labori, K. J. et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: a multicenter randomized phase-II trial (NORPACT-1). JCO 41, LBA4005–LBA4005 (2023).
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J. Med. 369, 1691–1703 (2013).
Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249–252 (2019).
pubmed: 30842658
pmcid: 6430113
Szkandera, J. et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br. J. Cancer 110, 183–188 (2014).
pubmed: 24201751
Luo, G. et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann. Surg. Oncol. 22, 670–676 (2015).
pubmed: 25155401
Zhang, K. et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J. Transl. Med. 17, 30 (2019).
pubmed: 30658662
pmcid: 6339361
Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
pubmed: 11229684
Tumeh, P. C. et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol. Res. 5, 417–424 (2017).
pubmed: 28411193
pmcid: 5749922
Shang, J. et al. Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade. Front. Oncol. 11, 585271 (2021).
Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer 8, e000842 (2020).
pubmed: 32581042
pmcid: 7312339
Wattenberg, M. M. et al. Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients. JCI Insight 6, e145389 (2021).
pubmed: 33497362
pmcid: 8021099
Rigamonti, N. et al. A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression. Cancer Immunol. Res. 10, 626–640 (2022).
pubmed: 35319751
Bossuyt, P. M. et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351, h5527 (2015).
pubmed: 26511519
pmcid: 4623764
McShane, L. M. et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Rev. Clin. Oncol. 2, 416–422 (2005).
Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–W102 (2017).
pubmed: 28407145
pmcid: 5570223